InMed Pharmaceuticals News

Press Releases

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

September 7, 2023

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

July 21, 2023

InMed Provides Update on BayMedica Rare Cannabinoid Business

July 20, 2023

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

June 22, 2023

InMed’s Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting

June 1, 2023

InMed to Participate in Upcoming Virtual Investor Events

May 24, 2023

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET

May 18, 2023

InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

May 15, 2023

InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

March 28, 2023

InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions

March 13, 2023

InMed to Participate in Upcoming Investor Events

March 7, 2023

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

February 17, 2023

InMed Submits Form 12b-25

February 9, 2023

InMed Provides Business Update and Milestones for 2023

January 10, 2023

InMed Announces Results of 2022 Annual General Meeting

December 15, 2022

InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

December 12, 2022

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

November 21, 2022

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

November 18, 2022

InMed Provides Update on Management Changes

November 17, 2022

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding

November 16, 2022

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Press Releases

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

InMed Provides Update on BayMedica Rare Cannabinoid Business

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

InMed’s Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting

InMed to Participate in Upcoming Virtual Investor Events

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET

InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions

InMed to Participate in Upcoming Investor Events

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

InMed Submits Form 12b-25

InMed Provides Business Update and Milestones for 2023

InMed Announces Results of 2022 Annual General Meeting

InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

InMed Provides Update on Management Changes

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive emails from InMed Pharmaceuticals